Skip to main content
. 2022 Feb;23(2):695–701. doi: 10.31557/APJCP.2022.23.2.695

Figure 3.

Figure 3

Overall Survival and Progression-Free Survival of the Patient Population Enrolled in this Study. (a)PFS and (b) OS according to the onset of immune related adverse events (irAEs). Solid line, grade 1-2 irAEs; dashed line, grade 3-4 irAEs; and dotted line, patients without irAEs. PFS, progression free survival; OS, overall survival